Evidence map›Paper›PMID 41811905›Full record

ArticleJournal of immunology research2026

SARS-CoV-2-Induced Macrophage Polarization Reverses HIV-1 Latency in J-Lat Cells Through TNFα Signaling.

Patricio Jarmoluk, Franco Agustín Sviercz, Cintia Cevallos, Rosa Nicole Freiberger, Cynthia Alicia López, M Victoria Delpino, Jorge Quarleri

Abstract read
In one paragraph

Article in Journal of immunology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Patricio JarmolukViral Immunopathology Laboratory, Institute for Biomedical Research on Retroviruses and AIDS (INBIRS), National Scientific and Technical Research Council (CONICET), University of Buenos Aires (UBA), Buenos Aires, Argentina, uba.ar.ORCID https://orcid.org/0009-0006-2844-2873
Franco Agustín SvierczViral Immunopathology Laboratory, Institute for Biomedical Research on Retroviruses and AIDS (INBIRS), National Scientific and Technical Research Council (CONICET), University of Buenos Aires (UBA), Buenos Aires, Argentina, uba.ar.
Cintia CevallosViral Immunopathology Laboratory, Institute for Biomedical Research on Retroviruses and AIDS (INBIRS), National Scientific and Technical Research Council (CONICET), University of Buenos Aires (UBA), Buenos Aires, Argentina, uba.ar.
Rosa Nicole FreibergerViral Immunopathology Laboratory, Institute for Biomedical Research on Retroviruses and AIDS (INBIRS), National Scientific and Technical Research Council (CONICET), University of Buenos Aires (UBA), Buenos Aires, Argentina, uba.ar.ORCID https://orcid.org/0009-0001-7461-5687
Cynthia Alicia LópezViral Immunopathology Laboratory, Institute for Biomedical Research on Retroviruses and AIDS (INBIRS), National Scientific and Technical Research Council (CONICET), University of Buenos Aires (UBA), Buenos Aires, Argentina, uba.ar.
M Victoria DelpinoViral Immunopathology Laboratory, Institute for Biomedical Research on Retroviruses and AIDS (INBIRS), National Scientific and Technical Research Council (CONICET), University of Buenos Aires (UBA), Buenos Aires, Argentina, uba.ar.ORCID https://orcid.org/0000-0003-2077-8509
Jorge QuarleriViral Immunopathology Laboratory, Institute for Biomedical Research on Retroviruses and AIDS (INBIRS), National Scientific and Technical Research Council (CONICET), University of Buenos Aires (UBA), Buenos Aires, Argentina, uba.ar.ORCID https://orcid.org/0000-0001-5110-8773

Funding

Agencia Nacional de Promoción Científica y Tecnológica PICTO-2021-00005-COVID SecuelasFundación Florencio Fiorini 2024
6 · The paper itself

Abstract

introductionCoronavirus disease 2019 (COVID-19) may have both short- and long-term impacts on the progression of human immunodeficiency virus (HIV)-1 after acute SARS-CoV-2 infection in people living with HIV (PLWH), even those on combined antiretroviral therapy (cART). This study aimed to investigate whether SARS-CoV-2 could influence HIV reactivation in latently infected lymphoid cells.

methodsHIV-infected lymphoid (J-Lat) cells, characterized by proviral latency under unstimulated conditions, were used for latency reversal assays with phorbol 12-myristate 13-acetate (PMA), free SARS-CoV-2 particles, or conditioned media (CM) from macrophages. Monocytes isolated from donor blood were differentiated into macrophages (monocyte-derived macrophages [MDMs]) and polarized to M1 or M2 phenotypes before stimulation or with two SARS-CoV-2 variants (wild-type and BA.5) infection. Additionally, the effects of redox imbalance on latency reversal in both J-Lat and myeloid (U1) latency models were measured. SARS-CoV-2 RNA was quantified by RT-qPCR targeting ORF1ab and N genes, and latency reversal and reactive oxygen species (ROS) levels were assessed by flow cytometry. TNFα involvement was confirmed through neutralization assays, while cytokines and polarization markers were analyzed via ELISA and fluorescent antibodies.

resultsJurkat and J-Lat cells had low ACE2 expression and were not permissive to SARS-CoV-2 infection. SARS-CoV-2 exposure alone did not induce HIV latency reversal in J-Lat cells. However, CM from M1-polarized, resiquimod (R-848)-treated, and SARS-CoV-2-infected macrophages significantly reactivated latent HIV. TNFα was identified as the primary driver of latency reversal, with no significant changes in ROS levels. Prolonged SARS-CoV-2 exposure shifted macrophage polarization toward an anti-inflammatory M2 phenotype, characterized by IL-10 release, which reduced latency reactivation.

conclusionsThis study demonstrates that SARS-CoV-2 can indirectly reverse HIV latency in lymphoid cells by promoting the release of pro-inflammatory cytokines from infected macrophages. These findings suggest potential therapeutic strategies for preventing HIV reactivation during SARS-CoV-2 coinfection, emphasizing the modulation of cytokine signaling to control inflammation while minimizing immune dysregulation.

Indexed as

COVID-19HIV-1HIV InfectionsMacrophagesSARS-CoV-2Tumor Necrosis Factor-alphaVirus LatencyHumansMacrophage ActivationReactive Oxygen SpeciesSignal TransductionVirus ActivationReactive Oxygen SpeciesTumor Necrosis Factor-alphaCOVID-19HIV latencyJ-Latmacrophage polarizationROSSARS-CoV-2TNFα

Identifiers

PMID41811905
PMCPMC13140423

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.